Piramal Pharma Solutions offer specialized services in the area of Clinical Trial Supply management. We provideprovide a range of clinical trial services that include clinical trial manufacturing, packaging and supply of APIs and Formulations. The services are offered for molecules in Phase I-III clinical trials

Piramal Pharma Solutions offers wide range of clinical analytical support services, including analytical method development, validation and transfer and also API chemical and physical properties.

Piramal Pharma offers pharmaceutical development services for various dosage forms like Oral solids, Semi-Solids, Sterile and Non-Sterile in US, UK and India.

Piramal Pharma Solutions experts offers pre-formulation studies in drug formulation with valuable information and suggestions to handle a wide range of compounds.

Piramal Pharma R&D services provide pharmaceutical intermediated and API development for new drug discovery and development solutions to the clients worldwide.

We provide Route scouting services with API development which minimize the waste and the cost OF API

"Piramal Pharma Solutions Analytical Chemistry Services offers Chiral purification-gram scale by Super Critical Fluid Chromatography, Prep HPLC Purification services, Impurity isolation and characterization & much more. we have committed analytical suites containing advanced analytical equipment and a team of over 55 analytical scientists. "

Piramal Pharma Solutions fully equipped kilo lab service allows for speedy advancement of scalable and robust chemical processes using progressive process technique to provide a quick supply in the early phase of the improvement.

Piramal Pharma Solutions offers best-in-class services for mg to gm scale with the help of medicinal chemistry requirements. Specialized team at Piramal Discovery Solutions is proficient in developing methodologies

Piramal Pharma Solutions In-Vitro facilities offer ADME services for providing faster & improved decision-making for chemistry clients. We offer economical customized and standardized assays as per the client’s requirement for ADME parameters.

Micronutrient deficiency is a lack of essential vitamins and minerals which are required in small am

Vitamins are organic substances required in small quantities for normal health and growth of an indi

Piramal Pharma Solutions offers antibody drug conjugate process development and scale-up through highly experienced team that has been working on ADCs over one decade. Find out more here.

Piramal Pharma Solutions offers early stage development service for ADC Program. Its cost-effective service to demonstrate the viability of cytotoxic drugs or monoclonal antibodies for use of therapeutic ADCs.

Piramal Pharma Solutions provide manufacture and supply of Active Pharmaceutical Ingredients on an integrated manufacturing model across North America, Europe and Asia.

Piramal Pharma Solutions offers HPAPI development and contract services through its FDA approved cGMP facility in Riverview, MI (USA). It offers full range of scale & containment options for HPAPIs.

Piramal Pharma solutions with strong development and regulatory capabilities, backed by accredited manufacturing sites, help customers in Late Pharmaceutical Life Cycle management of their products.

Piramal Pharma offers pharmaceutical development services for various dosage forms like Oral solids, Semi-Solids, Sterile and Non-Sterile in US, UK and India.

Piramal Pharma Solutions offers early stage development service for ADC Program. Its cost-effective service to demonstrate the viability of cytotoxic drugs or monoclonal antibodies for use of therapeutic ADCs.

Contract Development & Manufacturing Pharmaceutical company (CDMO) - Piramal Pharma Solutions, one of the leading pharmaceutical manufacturing companies in India established in 1984, offering contract manufacturing services covering drug life cycle from drug discovery to development. Contact us for further details.

An abstract is unavailable.

Original Article from The New England Journal of Medicine — A Comparison of Ceftriaxone and Cefuroxime for the Treatment of Bacterial Meningitis in Children

Chemical Entities of Biological Interest (ChEBI) is a freely available dictionary of molecular entities focused on 'small' chemical compounds.

Ceftriaxone as Home IV for Staph Infections - Full Text View.

Abstract. The aim of this study was to determine the pharmacokinetic profile of the normal recommended dose of ceftriaxone in critically ill patients and to est

Background Community-onset pneumonia (COP) is a combined concept of community acquired pneumonia and the previous classification of healthcare-associated pneumonia. Although ceftriaxone (CRO) is one of the treatment choices for COP, it is unclear whether 1 or 2 g CRO daily has better efficacy. We compared the effectiveness of 1 g with 2 g of CRO for COP treatment. We hypothesized that 1 g CRO would show non-inferiority over 2 g CRO. Methods This study was an analysis of prospectively registered data of the patients with COP from four Japanese hospitals (the Adult Pneumonia Study Group-Japan: APSG-J). We included subjects who were initially treated solely with 1 or 2 g of CRO. The propensity score was estimated from the 33 pre-treatment variables, including age, sex, weight, pre-existing comorbidities, prescribed drugs, risk factors for aspiration pneumonia, vital signs, laboratory data, and a finding from chest xrays. The primary endpoint was the cure rate, for which a non-inferiority analysis was performed with a margin of 0.05. In addition, we performed three sensitivity analyses; using data limited to the group in which CRO solely was used until the completion of treatment, using data limited to inpatient cases, and performing a generalized linear mixed-effect logistic regression analysis to assess the primary outcome after adjusting for random hospital effects. Results Of the 3817 adult subjects with pneumonia who were registered in the APSG-J study, 290 and 216 were initially treated solely with 1 or 2 g of CRO, respectively. Propensity score matching was used to extract 175 subjects in each group. The cure rate was 94.6 and 93.1% in the 1 and 2 g CRO groups, respectively (risk difference 1.5%; 95% confidence interval − 3.1 to 6.0; p = 0.009 for non-inferiority). The results of the sensitivity analyses were consistent with the primary result. Conclusions The propensity score-matched analysis of multicenter cohort data from Japan revealed that the cure rate for COP patients treated with 1 g daily CRO was non-inferior to that of patients treated with 2 g daily CRO.

The NICE British National Formulary (BNF) sites is only available to users in the UK, Crown Dependencies and British Overseas Territories